MAGEA8 Human
Description
MAGEA8 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Melanoma Antigen Family A, 8 (MAGEA8) is a member of the MAGEA gene family, which is part of the larger MAGE (Melanoma Antigen) family. These genes are known for their role in cancer biology, particularly in the context of cancer/testis (CT) antigens. MAGEA8, like other MAGEA genes, is primarily expressed in germline cells and various types of cancer cells, making it a significant target for cancer immunotherapy.
The MAGEA8 gene is located on the X chromosome at the Xq28 band . The gene encodes a protein that shares 50 to 80% sequence identity with other members of the MAGEA family . This high degree of similarity suggests that these proteins may have conserved functions, although the variability in their promoters and first exons indicates that they can be regulated differently depending on the cellular context .
MAGEA8 is expressed in a restricted manner, primarily in immune-privileged tissues such as the placenta and various cancers . This restricted expression pattern makes MAGEA8 an attractive target for cancer immunotherapy, as it minimizes the risk of off-target effects on normal tissues. The protein encoded by MAGEA8 is involved in various cellular processes, including cell cycle regulation and apoptosis, which are critical for cancer cell survival and proliferation .
MAGEA8, along with other MAGEA proteins, is associated with resistance to chemotherapy, metastasis, and increased survival potential of cancer cells . These characteristics make MAGEA8 a valuable target for designing specific and effective cancer immunotherapies. Strategies such as cancer vaccination and adoptive T-cell transfer are being explored to target MAGEA8 and other MAGEA proteins .
The immune-privileged nature and oncogenic activity of MAGEA8 make it a universal antigen capable of eliciting highly specific immune responses against cancer cells . Ongoing clinical trials and research are focused on developing therapies that target MAGEA8, with the aim of improving treatment outcomes for patients with various types of cancer .
